Modulation of Adhesion Molecules by Cholesterol-Lowering Therapy in Mononuclear Cells from Hypercholesterolemic Patients

Cardiovascular Therapeutics

Volumn 33, Issue 4, 2015, Pages 168-176

  Cerda, Alvaro ^a,b   Rodrigues, Alice Cristina ^a   Alves, Camila ^a   Genvigir, Fabiana Dalla Vecchia ^a   Fajardo, Cristina Moreno ^a   Dorea, Egidio Lima ^a   Gusukuma, Maria Cecilia ^a   Pinto, Gelba Almeida ^a   Hirata, Mario Hiroyuki ^a   Hirata, Rosario Dominguez Crespo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDAD DE LA FRONTERA   (Chile)

Author keywords

Adhesion molecules; Cholesterol lowering; Ezetimibe; Hypercholesterolemia; Statins

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CD11B ANTIGEN; CELL ADHESION MOLECULE; CHOLESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; L SELECTIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MESSENGER RNA; P SELECTIN GLYCOPROTEIN LIGAND 1; SIMVASTATIN; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4; BIOLOGICAL MARKER; EZETIMIBE PLUS SIMVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG SYNTHESIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MODULATION; MONONUCLEAR CELL; MONOTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGED; BLOOD; CELL LINE; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; GENETICS; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

AGED; ATORVASTATIN CALCIUM; BIOMARKERS; CELL ADHESION MOLECULES; CELL LINE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; EZETIMIBE; EZETIMIBE, SIMVASTATIN DRUG COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RNA, MESSENGER; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84935479612     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12126     Document Type: Article

References (29)

1. Weber C, Noels H. Atherosclerosis: Current pathogenesis and therapeutic options. Nat Med 2011;17:1410-1422.
2. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: Transition from theory to practice. Circ J 2010;74:213-220.
3. van Gils JM, Zwaginga JJ, Hordijk PL. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol 2009;85:195-204.
4. Kansas GS. Selectins and their ligands: Current concepts and controversies. Blood 1996;88:3259-3287.
5. Hidalgo A, Peired AJ, Wild MK, Vestweber D, Frenette PS. Complete identification of E-selectin ligands on neutrophils reveals distinct functions of PSGL-1, ESL-1, and CD44. Immunity 2007;26:477-489.
6. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: The leukocyte adhesion cascade updated. Nat Rev Immunol 2007;7:678-689.
7. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
8. Zhou Q, Liao JK. Pleiotropic effects of statins - Basic research and clinical perspectives. Circ J 2010;74:818-826.
9. Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: Molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 2012;18:1519-1530.
10. Yamazaki D, Ishida M, Watanabe H, et al. Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe. Lipids Health Dis 2013;12:9.
11. Westerink J, Deanfield JE, Imholz BP, et al. High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study. Atherosclerosis 2013;227:118-124.
12. Ye Y, Zhao X, Zhai G, Guo L, Tian Z, Zhang S. Effect of high-dose statin versus low-dose statin plus ezetimibe on endothelial function: A meta-analysis of randomized trials. J Cardiovasc Pharmacol Ther 2012;17:357-365.
13. Bays HE, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: Cholesterol lowering and beyond. Expert Rev Cardiovasc Ther 2008;6:447-470.
14. Kohno T. Report of the American Heart Association (AHA) scientific sessions 2014, Chicago. Circ J 2014;79:34-40.
15. Cerda A, Genvigir FD, Rodrigues AC, et al. Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression. J Atheroscler Thromb 2011;18:640-651.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408.
17. Sampalis JS, Bissonnette S, Boukas S. Effecti-veness of ezetimibe in reducing the estimated risk for fatal cardiovascular events in hypercholes-terolaemic patients with inadequate lipid control while on statin monotherapy as measured by the SCORE model. Adv Prev Med 2011;2011:597163.
18. Krysiak R, Zmuda W, Okopien B. The effect of simvastatin-ezetimibe combination therapy on adipose tissue hormones and systemic inflam-mation in patients with isolated hyper-cholesterolemia. Cardiovasc Ther 2014;32:40-46.
19. Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: Mechanism of action and clinical update. Vasc Health Risk Manag 2012;8:415-427.
20. Orsó E, Werner T, Wolf Z, Bandulik S, Kramer W, Schmitz G. Ezetimib influences the expression of raft-associated antigens in human monocytes. Cytometry A 2006;69:206-208.
21. Gómez-Garre D, Muñoz-Pacheco P, González-Rubio ML, Aragoncillo P, Granados R, Fernández-Cruz A. Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect. Br J Pharmacol 2009;156:1218-1227.
22. Assmann G, Gotto AM. HDL cholesterol and protective factors in atherosclerosis. Circulation 2004;109(23 Suppl 1):III8-III14.
23. Walter T, Suselbeck T, Borggrefe M, Swoboda S, Hoffmeister HM, Dempfle CE. Effect of atorvastatin on cellular adhesion molecules on leukocytes in patients with normocholesterolemic coronary artery disease. In Vivo 2010;24:189-193.
24. Rezaie-Majd A, Prager GW, Bucek RA, et al. Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2003;23:397-403.
25. Serrano CV Jr, Pesaro AE, de Lemos JA, et al. Native LDL-cholesterol mediated monocyte adhe-sion molecule overexpression is blocked by sim-vastatin. Cardiovasc Drugs Ther 2009;23:215-220.
26. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997;30:1212-1217.
27. Stavroulopoulos A, Petras D, Kakavas I, et al. Monocyte expression of adhesion molecules during low- and high-flux polysulfone hemodialysis and the effect of atorvastatin administration. Blood Purif 2010;29:274-279.
28. Huo Y, Xia L. P-selectin glycoprotein ligand-1 plays a crucial role in the selective recruitment of leukocytes into the atherosclerotic arterial wall. Trends Cardiovasc Med 2009;19:140-145.
29. Volcik KA, Catellier D, Folsom AR, Matijevic N, Wasserman B, Boerwinkle E. SELP and SELPLG genetic variation is associated with cell surface measures of SELP and SELPLG: The Atherosclerosis Risk in Communities Carotid MRI Study. Clin Chem 2009;55:1076-1082.